World News: 22:05 GMT Wednesday 15th May 2019. [Atara Biotherapeutics, Inc. via Globe Newswire via SPi World News]
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced three presentations at the upcoming ASCO 2019 Annual Meeting, which will take place in Chicago, Illinois from May 31 to June 4, 2019.
An oral session will feature a presentation by Atara’s collaborators at Memorial Sloan Kettering Cancer Center (MSK) with additional Phase 1 clinical results for their regionally delivered autologous mesothelin-targeted chimeric antigen receptor T-cell (CAR T) immunotherapy for patients with malignant pleural mesothelioma.
Atara will also present two studies highlighting tab-cel (tabelecleucel), the Company’s product candidate in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors.
One study describes a potential biomarker for clinical response to tab-cel in patients with Epstein-Barr virus-associated diseases. A second presentation focuses on the design of Atara’s ongoing Phase 1b/2 clinical study design of tab-cel in combination with KEYTRUDA® (pembrolizumab) for patients with platinum-resistant or recurrent EBV-associated nasopharyngeal carcinoma (NPC).
Details of the presentations are as follows:
John Grimaldi, Burns McClellan212-213-0006 x362
Globe Newswire: 22:05 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.